drugset
drugset / Trial / NCT00955981

Gout Dose Response Study

NCT00955981 ↗

Phase 2 Completed 123 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the proportion of subjects whose serum urate (sUA) level is \< 6.0 mg/dL after 28 days of dosing by treatment group.

Timeline

Start
2009-07
Primary completion
2010-03
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 200 mg —
Subject Lesinurad Small molecule 400 mg —
Subject Lesinurad Small molecule 600 mg —

Indications

No indication recorded.